BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

...macrophage colony-stimulating factor (GM-CSF; CSF2) (lenzilumab or murine anti-GM-CSF) ALL Preclinical 961 Mayo Clinic / Tolero Pharmaceuticals Inc....
BioCentury | Mar 31, 2017
Politics, Policy & Law

Balancing act

...Kure Corp. T.R. Winston & Co. Lillis Energy Inc. Tivorsan Pharmaceuticals Inc. (B) MedAvante Inc. Tolero Pharmaceuticals Inc....
...Partners Inc. Social Reality Inc. Strike Bio Inc. Synthesis Energy Systems Inc. Tivorsan Pharmaceuticals Inc. Tolero Pharmaceuticals Inc....
BioCentury | Dec 30, 2016
Company News

Sumitomo, Tolero deal

...in fiscal year 2018 beginning April 1, 2018. The companies declined to provide further details. Tolero Pharmaceuticals Inc....
...Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Business: Cancer, Hematology Jaime De Leon alvocidib Sumitomo Dainippon Pharma Co. Ltd. Tolero Pharmaceuticals Inc. Cyclin...
BioCentury | Dec 22, 2016
Company News

Sumitomo acquiring Tolero

...Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) will acquire oncology and hematology company Tolero Pharmaceuticals Inc. (Lehi, Utah) for...
...under a 2013 deal. The acquisition is expected to close in February. Jaime De Leon alvocidib Merrimack Pharmaceuticals Inc. Tolero Pharmaceuticals Inc. Cyclin...
BioCentury | Dec 15, 2016
Targets & Mechanisms

Keeping the Gas off AXL

...AXL inhibitor NSCLC; AML Phase I Qurient Co. Ltd. (KOSDAQ:115180) Q-4 AXL inhibitor Cancer Preclinical Tolero Pharmaceuticals Inc....
BioCentury | Nov 2, 2016
Distillery Therapeutics

Cancer

...a conditionally active biologic (CAB) targeting AXL, in preclinical testing to treat solid tumors. Tolero Pharmaceuticals Inc....
...doi:10.1126/scisignal.aaf8175 CONTACT: Ruby Yun-Ju Huang, National University of Singapore, Singapore email: ruby_yj_huang@nuhs.edu.sg Esme Gaisford BGB324 CAB-AXL-ADC TP-0903 BioAtla LLC Rigel Pharmaceuticals Inc. Tolero Pharmaceuticals Inc....
BioCentury | Sep 29, 2016
Distillery Therapeutics

Therapeutics: Caspase-3 (CASP3; CPP32); cyclin dependent kinase (CDK)

...and Phase II testing for acute myelogenous leukemia (AML) and five other cancers. Sanofi and Tolero Pharmaceuticals Inc....
BioCentury | Dec 14, 2015
Product Development

Following CoMMpass

...reviewing the results to determine how they might affect a potential regulatory path for AT7519. Tolero Pharmaceuticals Inc....
...Japan Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Tokyo, Japan Translational Genomics Research Institute (TGEN), Phoenix, Ariz. Tolero Pharmaceuticals Inc....
BioCentury | Nov 23, 2015
Company News

Eutropics, Tolero Pharmaceuticals deal

...not respond to inquiries (see BioCentury, Jan. 20, 2014). Eutropics Pharmaceuticals Inc. , Cambridge, Mass. Tolero Pharmaceuticals Inc....
BioCentury | Nov 24, 2014
Financial News

Tolero Pharmaceuticals financial update

Tolero Pharmaceuticals Inc. , Lehi, Utah Business: Cancer, Autoimmune Date announced: 2014-11-05 Note: Tolero raised $7.8 million in a second tranche of a series B financing, bringing the total raised in the round to $22.4 million....
Items per page:
1 - 10 of 25
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

...macrophage colony-stimulating factor (GM-CSF; CSF2) (lenzilumab or murine anti-GM-CSF) ALL Preclinical 961 Mayo Clinic / Tolero Pharmaceuticals Inc....
BioCentury | Mar 31, 2017
Politics, Policy & Law

Balancing act

...Kure Corp. T.R. Winston & Co. Lillis Energy Inc. Tivorsan Pharmaceuticals Inc. (B) MedAvante Inc. Tolero Pharmaceuticals Inc....
...Partners Inc. Social Reality Inc. Strike Bio Inc. Synthesis Energy Systems Inc. Tivorsan Pharmaceuticals Inc. Tolero Pharmaceuticals Inc....
BioCentury | Dec 30, 2016
Company News

Sumitomo, Tolero deal

...in fiscal year 2018 beginning April 1, 2018. The companies declined to provide further details. Tolero Pharmaceuticals Inc....
...Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Business: Cancer, Hematology Jaime De Leon alvocidib Sumitomo Dainippon Pharma Co. Ltd. Tolero Pharmaceuticals Inc. Cyclin...
BioCentury | Dec 22, 2016
Company News

Sumitomo acquiring Tolero

...Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) will acquire oncology and hematology company Tolero Pharmaceuticals Inc. (Lehi, Utah) for...
...under a 2013 deal. The acquisition is expected to close in February. Jaime De Leon alvocidib Merrimack Pharmaceuticals Inc. Tolero Pharmaceuticals Inc. Cyclin...
BioCentury | Dec 15, 2016
Targets & Mechanisms

Keeping the Gas off AXL

...AXL inhibitor NSCLC; AML Phase I Qurient Co. Ltd. (KOSDAQ:115180) Q-4 AXL inhibitor Cancer Preclinical Tolero Pharmaceuticals Inc....
BioCentury | Nov 2, 2016
Distillery Therapeutics

Cancer

...a conditionally active biologic (CAB) targeting AXL, in preclinical testing to treat solid tumors. Tolero Pharmaceuticals Inc....
...doi:10.1126/scisignal.aaf8175 CONTACT: Ruby Yun-Ju Huang, National University of Singapore, Singapore email: ruby_yj_huang@nuhs.edu.sg Esme Gaisford BGB324 CAB-AXL-ADC TP-0903 BioAtla LLC Rigel Pharmaceuticals Inc. Tolero Pharmaceuticals Inc....
BioCentury | Sep 29, 2016
Distillery Therapeutics

Therapeutics: Caspase-3 (CASP3; CPP32); cyclin dependent kinase (CDK)

...and Phase II testing for acute myelogenous leukemia (AML) and five other cancers. Sanofi and Tolero Pharmaceuticals Inc....
BioCentury | Dec 14, 2015
Product Development

Following CoMMpass

...reviewing the results to determine how they might affect a potential regulatory path for AT7519. Tolero Pharmaceuticals Inc....
...Japan Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Tokyo, Japan Translational Genomics Research Institute (TGEN), Phoenix, Ariz. Tolero Pharmaceuticals Inc....
BioCentury | Nov 23, 2015
Company News

Eutropics, Tolero Pharmaceuticals deal

...not respond to inquiries (see BioCentury, Jan. 20, 2014). Eutropics Pharmaceuticals Inc. , Cambridge, Mass. Tolero Pharmaceuticals Inc....
BioCentury | Nov 24, 2014
Financial News

Tolero Pharmaceuticals financial update

Tolero Pharmaceuticals Inc. , Lehi, Utah Business: Cancer, Autoimmune Date announced: 2014-11-05 Note: Tolero raised $7.8 million in a second tranche of a series B financing, bringing the total raised in the round to $22.4 million....
Items per page:
1 - 10 of 25